SubsidieMeestersCataract Simulator Diagnostics Device Development Using Computational Holographic Displays
Developing a holographic vision simulator for cataract patients to evaluate multifocal IOLs through in-vivo testing and clinical studies.
Projectdetails
Introduction
Cataracts are the most prevalent blinding disease in the world. Surgery is the only option for cataracts, and it is the most frequently performed surgery worldwide.
Problem Statement
However, how the patient will see after surgery and what type of replacement intraocular lens (IOL) is the best option cannot be known.
Project Overview
In this project, computational holography will be utilized to develop a holographic vision simulator for cataract patients. This technology can control the phase, size, and shape of the light beam entering through the eye pupil.
Objectives
- Develop a holographic vision simulator for cataract patients.
- Create the first cataract simulator for in-vivo testing of multifocal IOLs.
- Perform clinical studies of the novel instrument on patients.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.010.200 |
| Totale projectbegroting | € 2.010.200 |
Tijdlijn
| Startdatum | 1-4-2022 |
| Einddatum | 30-6-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- KOC UNIVERSITYpenvoerder
- CY VISION TEKNOLOJI SANAYI ANONIM SIRKETI
- FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN-NUERNBERG
- OSPEDALE SAN RAFFAELE SRL
- UNIVERSITATSKLINIKUM ERLANGEN
Land(en)
Vergelijkbare projecten binnen EIC Transition
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Targeting cardiac fibrosis with next generation RNA therapeuticsFIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness. | EIC Transition | € 2.499.482 | 2022 | Details |
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationSThe NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring. | EIC Transition | € 2.497.750 | 2022 | Details |
Predictive REagent-Antibody Replacement Technology stage 2-TranslationPRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment. | EIC Transition | € 800.000 | 2022 | Details |
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stageDeveloping a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships. | EIC Transition | € 2.499.810 | 2022 | Details |
Targeting cardiac fibrosis with next generation RNA therapeutics
FIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness.
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationS
The NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring.
Predictive REagent-Antibody Replacement Technology stage 2-Translation
PRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment.
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stage
Developing a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Retinal Mesh OptoelectronicsThe project aims to develop a novel Retinal Mesh Optoelectronics using quantum dots and nanowires for flexible, high-density implants to restore vision in patients with photoreceptor degeneration. | ERC COG | € 2.000.000 | 2022 | Details |
Optical imaging platform for high-throughput longitudinal studies of the eye in disease modelsThe OPTIMEYEZ project aims to enhance a novel multi-contrast optical imaging platform for non-invasive retinal studies, facilitating drug development in neurological diseases while reducing animal use. | ERC POC | € 150.000 | 2023 | Details |
Polymer pRobes fOr a VISual prOsthesisPROVISO aims to develop flexible polymer electrodes for chronic implantation in the visual cortex to restore rudimentary vision in blind individuals by inducing artificial light perception. | ERC POC | € 150.000 | 2024 | Details |
New era of guided lens implantation in cataract surgeryAkknaTek's imaging technology enhances cataract surgery by ensuring precise lens placement through a comprehensive three-module system for pre-operative screening, real-time monitoring, and post-operative adjustments. | EIC Accelerator | € 2.289.875 | 2023 | Details |
Retinal Mesh Optoelectronics
The project aims to develop a novel Retinal Mesh Optoelectronics using quantum dots and nanowires for flexible, high-density implants to restore vision in patients with photoreceptor degeneration.
Optical imaging platform for high-throughput longitudinal studies of the eye in disease models
The OPTIMEYEZ project aims to enhance a novel multi-contrast optical imaging platform for non-invasive retinal studies, facilitating drug development in neurological diseases while reducing animal use.
Polymer pRobes fOr a VISual prOsthesis
PROVISO aims to develop flexible polymer electrodes for chronic implantation in the visual cortex to restore rudimentary vision in blind individuals by inducing artificial light perception.
New era of guided lens implantation in cataract surgery
AkknaTek's imaging technology enhances cataract surgery by ensuring precise lens placement through a comprehensive three-module system for pre-operative screening, real-time monitoring, and post-operative adjustments.